Connor Iapoce

Current approaches to vision screening in the US may not sufficiently cater to children of all sociodemographic backgrounds.

A Mendelian randomization study suggests a link between genetically lower iron levels and the risk of subsequently developing celiac disease.

Anemia showed an association with disability and suboptimal functional outcomes, but no association with neurological deficit or mortality, at 90 days post-stroke.

A review of 15 RCTS suggests that both electroacupuncture and conventional drugs demonstrate similar effectiveness in addressing pain for patients with acute gouty arthritis.

Addressing isolation and loneliness indexes resulted in a decreased risk of all-cause mortality among individuals with obesity in the UK Biobank.

Childhood trauma may decrease the likelihood of optimal heart health in adulthood, while stable and nurturing experiences are shown to promote heart health.

Mortality risks in gout have not improved in the United States in the past 3 decades, with a similar risk found among contemporary cases of gout in the United Kingdom.

A limited number of eyes with advanced pediatric vitreoretinal diseases exhibited decreased vascular activity after intra-anterior chamber injections of ranibizumab.

Observational data from the ARIC study reveals that lower plasma levels correlate with an increased risk of incident heart failure and diastolic dysfunction.

Patients with uveitis switched from adalimumab originator to SB5 did not experience clinically significant differences in treatment efficacy and safety.

Real-life data reveal the effectiveness of TNF-inhibitor biosimilars in minimizing ocular flares and preserving visual acuity in pediatric patients with uveitis.

Pivotal clinical trials associated with FDA ophthalmic drug approval were found to underreport and conflate sex and gender in analysis.

A new study reports previously unknown inherited genetic variants that contribute to glaucoma risk among more than 11,000 people of African ancestry.

Both the FDA and EU regulators indicated visual acuity may serve as primary endpoint to evaluate MCO-010 in the treatment of low-vision retinitis pigmentosa patients.

An analysis of the RAFT trial showed patients with heart failure treated with CRT-D experienced continued survival benefits during a median of nearly 14 years of follow-up.

Fracture occurrences were numerically higher among men who received testosterone than placebo across a subtrial of the phase 4 TRAVERSE trial.

Exposure to higher levels of outdoor artificial light at night exhibited an increased risk of incident wet age-related macular degeneration.

BIOS-ROP study results indicate the bevacizumab biosimilar monotherapy leads to complete ROP regression in almost two-third of the eyes after 24 weeks of treatment.

The FDA grants the company agreement under a Special Protocol Assessment to evaluate TRS01 ophthalmic solution for the treatment of non-infectious uveitis, including uveitic glaucoma.

Prescribing phosphodiesterase type 5 inhibitors and nitrates together may increase the risk of morbidity and mortality for patients over time.

Autonomous AI increases diabetic eye exam completion rates in a diverse population of youth with diabetes.

A local corticosteroid burst followed by 0.18 mg FAi may be a useful adjuvant for the treatment of noninfectious uveitis, but not sufficient as solo therapy.

Moderate-to-severe anemia decreased the likelihood of a favorable outcome after mechanical thrombectomy compared with no anemia.

The novel topical dry eye disease candidate achieved a statistically significant ≥10-mm increase in unanesthetized Schirmer’s score at Day 14.

Two-year XTEND trial data shows proactive aflibercept led to meaningful functional and anatomic improvements that were maintained across the study period.

Patients with lung cancer treated with EGFR inhibitors may experience a greater risk for keratitis, particularly with afatinib treatment.

A meta-analysis of RCTs revealed significant advantages with faricimab treatment in improving CST and reducing injection frequency among eyes with AMD or DME.

Positive interim data from the TEASE-3 clinical trial show gildeuretinol slows the progression of Stargardt Disease for up to six years.

A meta-analysis of 14 randomized trials suggests a beneficial effect of intravenous iron on cardiovascular mortality and heart failure readmissions.

A multidisciplinary panel assembled by the Society for Cardiovascular Angiography & Interventions examined and supported the role of intravascular ultrasounds in lower extremity revascularization procedures.